Safety of fluralaner oral solution, a novel systemic poultry red mite treatment, for chicken breeders’ reproductive performances

Abstract Background Poultry mites are the most significant pest affecting production systems in the chicken egg-laying industry, altering the health condition of the birds, and causing stress, mortality and decline of egg quality impacting economic performance. Fluralaner is a novel systemic parasiticide that is effective against poultry mites (Dermanyssus gallinae, Ornithonyssus sylviarum) in chickens after oral administration. The evaluation of the safety of this new product in breeder chickens is particularly relevant because poultry mite infestation affects long cycle production systems, such as layers and breeders farms, for which the productivity heavily depends on the health of the reproductive function. This study was designed to investigate the safety for reproductive performances of fluralaner in male and female chickens at 3 times the recommended dose (1.5 instead of 0.5 mg/kg body weight) and 2 times the recommended duration (4 administrations instead of 2 administrations, with a 7 day interval between administrations). Methods This randomized, parallel-group, blinded study included 432 Bovans brown parent stock chickens (48 males and 384 females, 17-week old). Birds were randomly assigned to 16 pens (three males and 24 females per pen), and then each pen assigned to one of the two treatment groups (8 pens, i.e. 216 birds per group). Fluralaner was administered via drinking water on a total of four occasions 7 days apart, at daily doses of 1.5 mg fluralaner/kg body weight, equivalent to 3 times the recommended dose of fluralaner per administration and 2 times the recommended number of administrations. Birds supplied with non-medicated drinking water served as controls. The treatments were given at time of peak egg production in the bird’s life: i.e. at 30 to 34 week of age. During that period, all adult chickens were clinically observed. The reproductive performances were carefully monitored including the number of eggs laid, egg weight, fertility and hatchability. Furthermore, the health and viability (up to 14 days of life) of randomly selected chicks was also monitored. Results There were no clinical findings related to fluralaner treatment. There were no statistically significant differences between the reproductive performances of treated and control groups, nor in their progeny chickens viability. Conclusions Oral administration of fluralaner was well tolerated by breeder chickens with a safety margin of approximately 3-fold obtained. Fluralaner had no effect on the egg number, weight and fertility, and no effect on egg hatchability or chick viability. Based on these results, a safe use of the new mite treatment proposed with fluralaner administered via drinking water is expected in layer and breeder field industrial conditions

Behavioural modelling of MEMS oscillators and phase noise simulation

International audienc